Migraine patients may exhibit a systemic pathophysiological alteration, according to a recently published clinical investigation. The study, was conducted by Dr. Willebrordus PJ van Oosterhout, from Leiden University Medical Centre Department of Neurology. Nitroglycerin (NTG) is a potent vasodilator and is known to induce migraine attacks in migraine patients. Because of its vasodilating properties, NTG… Read more

Inhaled cannabis reduces self-reported headache severity by 47.3% and migraine severity by 49.6%, a recent study from Washington State University found. “We were motivated to do this study because a substantial number of people say they use cannabis for headache and migraine, but surprisingly few studies had addressed the topic,” said Carrie Cuttler, the lead… Read more

New twelve-month data from a phase 3 clinical trial of eptinezumab in episodic migraine patients has been released. The results show that patients experienced even further reductions in migraine following the third and fourth quarterly infusions at both dose levels (100mg and 300mg) of the drug, Alder’s lead investigational product candidate for migraine prevention targeting… Read more

Relief, in the form of a new drug, may be on the horizon for those who have tried in vain to prevent migraine with other treatments, a preliminary study suggests. Novartis has announced full results from the Phase IIIb LIBERTY trial of Aimovig (erenumab, AMG 334) in episodic migraine patients who had previously failed two… Read more

Fremanezumab, a humanized monoclonal antibody, cuts the frequency of migraine headaches, a study of the new long-acting drug showed. The phase III HALO clinical trial evaluated the efficacy, safety and tolerability of two subcutaneous dose regimens of fremanezumab for the preventive treatment of chronic migraine. Teva Pharmaceutical Industries, the company developing the drug, hopes for… Read more